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Abstract
Background: Avoidance of unnecessary antimicrobial administration is a key tenet of antimicrobial stewardship;
knowing the optimal duration of therapy obviates over-treatment. However, little research has been performed to
establish course lengths for common canine infections. In clinical practice, antimicrobial therapy is frequently
prescribed in dogs presenting lower urinary tract signs (haematuria, pollakiuria and dysuria/stranguria). The
proposed length of treatment in International Consensus guidelines has decreased with each iteration, but these
recommendations remain arbitrary and largely extrapolated from experience in people.
Methods: The objective of this prospective, multi-centre study is to find the shortest course duration that is non-
inferior to the standard duration of 7 days of amoxicillin/clavulanate in terms of clinical outcomes for female dogs
with lower urinary tract signs consistent with a urinary tract infection. An electronic data capture platform will be
used by participating veterinarians working in clinical practice in the United Kingdom. Eligible dogs must be female,
aged between 6 months and 10 years and have lower urinary tract signs of up to seven days’ duration. Enrolment
will be offered in cases where the case clinician intends to prescribe antimicrobial therapy. Automatic pseudo-
randomisation to treatment group will be based on the day of presentation (Monday-Friday); all antimicrobial
courses will be completed on the Sunday after presentation generating different treatment durations. Follow-up
data will be collected 1, 8 and 22–26 days after completion of the antimicrobial course to ensure effective safety
netting, and to monitor short-term outcome and recurrence rates. Informed owner consent will be obtained in all
cases. The study is approved by the Ethical Review Board of the University of Nottingham and has an Animal Test
Certificate from the Veterinary Medicine’s Directorate.
Discussion: This study has been designed to mirror current standards of clinical management; conclusions should
therefore, be widely applicable and guide practising veterinarians in their antimicrobial decision-making process. A
duration-response curve will be created allowing determination of the optimal treatment duration for the
management of female dogs with lower urinary tract signs. It is hoped that these results will contribute valuable
information to improve future antimicrobial stewardship as part of a wider one-health perspective.
Keywords: Antimicrobial stewardship, Antimicrobial resistance, duration, Urinary tract infection, Canine, Duration-
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Background
The therapeutic value of antimicrobials has been amply
demonstrated over the past century both in lives saved
and suffering alleviated. However, the continued success
of antimicrobial therapy now hangs in the balance due
to developing antimicrobial resistance (AMR). AMR is
estimated to cause over 30,000 deaths and almost
900,000 disability-adjusted life-years (DALYs) a year in
the EU and EEA alone. This estimated burden of AMR
– excluding tuberculosis - is similar to the annual cumu-
lative burden of influenza, tuberculosis and human im-
munodeficiency virus (HIV) [1]. In recognition of the
role of antimicrobial use in driving AMR, antimicrobial
stewardship initiatives have been developed to try to
guide prescribers to optimise their antimicrobial use. For
veterinarians these tools include the British Small Ani-
mal Veterinary Association (BSAVA)/Small Animal
Medicine Society (SAMSoc) PROTECT ME poster, Fed-
eration of European Companion Animal Veterinary As-
sociations (FECAVA) guidelines and the Danish
Antimicrobial Use Guidelines for Companion Animal
Practice [2]. Recommendations are derived from the lim-
ited evidence available in the literature and consensus
statements such as the guidelines produced by the Inter-
national Society for Companion Animal Infectious Dis-
eases (ISCAID) [3–5].
Bacterial urinary tract infection (UTI), whether pre-
sumptive or confirmed, is a common motive for consult-
ation in small animal practice and accounts for 6–12 %
of antimicrobial prescriptions in dogs [6–9]. A lifetime
prevalence of UTI of 14 % has been reported in dogs
[10] with a marked predisposition among females [10,
11] due to the shorter urethral length and increased inci-
dence of bacteriuria compared to males [12]. Clinical
suspicion of a UTI is based on the presentation of com-
patible lower urinary tract signs (pollakiuria, dysuria/
stranguria and haematuria). However, these signs are
not pathognomonic for the presence of infection, with
only 46 to 65 % of dogs with one or more clinical signs
of lower urinary tract disease having infection confirmed
at culture [13–15].
The previous classification system for canine UTIs, ex-
trapolated from human medicine, described uncompli-
cated or complicated infections [16]. However,
prolonged treatment with an antimicrobial as recom-
mended for a complicated UTI is not always warranted.
Recently, a new nomenclature system has been intro-
duced, defining all initial or infrequent (< 3 episodes of
cystitis in the preceding year) presentations in non-
gravid females as ‘canine sporadic cystitis’ even if urinary
tract abnormalities or comorbidities are present [5]. The
emphasis in the new terminology is on the presence of
inflammation and consequent compatible clinical signs
[5]. Subclinical bacteriuria is thereby excluded; it is
recommended to avoid antimicrobial therapy in the ab-
sence of lower urinary tract signs [5].
Bacterial culture and antimicrobial susceptibility test-
ing can be performed to demonstrate bacterial involve-
ment and to optimise antimicrobial selection. However,
empirical therapy is typically commenced pending cul-
ture results. While antimicrobial stewardship guidelines
and the ISCAID guidelines advocate submitting samples
for culture in all cases of sporadic cystitis, it is recog-
nised that this may not occur routinely in practice. In
the PROTECT ME guidelines, culture is strongly advised
but not deemed essential for cases of uncomplicated
cystitis. To the authors’ knowledge, the proportion of
dogs treated for suspected UTI that have a confirmatory
culture has not been determined. Research in human
medicine found that cultures were requested in only 10–
40 % of cases of suspected UTI despite high levels (74–
94 %) of antimicrobial use [17–19]. In one study, out of
1148 cats treated with cefovecin (157 with clinical signs
relating to the urinary tract), bacterial culture was per-
formed only 4 times [20]. While these examples illus-
trate a stark divergence between guideline
recommendations and standard practice, they offer a
representative reflection of the decision-making associ-
ated with antimicrobial prescription.
According to the latest data from the European Medi-
cines Agency, amoxicillin/clavulanate is the most com-
monly prescribed antimicrobial tablet in Europe [21]. It
accounted for 44 % of antimicrobial prescriptions in
first-opinion practices in the UK [22]. Amoxicillin is a
time-dependent antimicrobial with a broad spectrum of
action against Gram positive and Gram negative bacteria
that commonly cause UTI in dogs. In recent studies in
the UK and USA, approximately 50–75 % of pathogen
isolates were sensitive to amoxicillin/clavulanate with
rates of up to 90 % in uncomplicated cases [23, 24].
These figures are likely to underestimate biological sen-
sitivity as amoxicillin is concentrated in urine potentially
overcoming some of the resistance of beta-lactamase
producing bacteria [5]. Urine drug concentrations ob-
tained following administration of standard doses of an-
timicrobials have been published for healthy animals
[25]. Susceptibility of an identified uropathogen may be
anticipated if the achieved concentration exceeds the
minimum inhibitory concentration (MIC) in vitro.
Amoxicillin/clavulanate, used for 10–14 days to treat
confirmed bacterial UTI in dogs, had a clinical cure rate
of approximately 70–80 % and microbiological cure rates
of 85–90 % [26, 27]. Short antimicrobial regimens of 3
days of either enrofloxacin or trimethoprim/
sulphonamide were not inferior to either 14 days of
amoxicillin/clavulanate or 10 days of cephalexin respect-
ively in dogs with bacterial UTI [27, 28]. These studies,
demonstrate that effective clinical and microbiological
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cure may be achieved in most cases of sporadic cystitis
with short courses of antimicrobial therapy, at least for
these particular antimicrobials. The recommended dur-
ation for treatment stated in the marketing authorisa-
tions for amoxicillin/clavulanate of 5–7 days is not
supported by published evidence in the veterinary litera-
ture. Despite the commonness of this condition, robust
data to inform the optimal duration of antimicrobial
treatment are still lacking [29].
An emerging dogma in human medicine, in relation to
duration of antimicrobial treatment, asserts that shorter
is better [30, 31]. Nevertheless, general practitioners
often prescribe longer courses than the duration recom-
mended in national guidelines [32]. Administration of
antimicrobials beyond what is necessary to achieve clin-
ical resolution risks fostering AMR at remote sites (in-
cluding the microbiome) due to sustained antimicrobial
exposure and thus selective pressure favouring resist-
ance. In human patients with pneumonia, excess treat-
ment was not associated with improved outcomes (lower
death rates or risks of recurrence) but did incur a 5 % in-
crease in the likelihood of drug-related adverse events
[33].
Mirroring this principle, the consensus recommenda-
tion from the latest ISCAID guidelines advocates a dur-
ation of antimicrobial treatment of just 3–5 days for
sporadic cystitis [5]. Standardised course lengths (often
arbitrarily based on multiples of 5 or 7 days) offer less
flexibility than a tailored approach of treating until (or
just beyond) clinical cure. However, such a dynamic ap-
proach relies heavily on the capacity of an owner to ac-
curately interpret their pet’s clinical signs to inform their
decision to stop treatment. Robust evidence supporting
shorter antimicrobial course lengths is required to
optimize antimicrobial therapy in dogs.
In summary, findings from past research and extrapo-
lation from current practice in human medicine provides
support for the adoption of shorter antimicrobial
courses. However, robust evidence is required to deter-
mine the optimal duration of treatment for sporadic
cystitis so that veterinarians can manage these patients
with confidence. The rationale of the current study is to
provide meaningful data relevant to current standard
practice and to guide a single aspect of antimicrobial
prescription. Since an intention to treat with antimicro-
bials is a pre-requisite inclusion criterion, the study is fo-
cused on comparing clinical outcomes to different
durations of therapy.
The primary objective of the study is to estimate the
shortest antibiotic treatment duration (out of 3, 4, 5, 6
days) that is non-inferior to 7 days of treatment with
amoxicillin/clavulanate in terms of clinical cure among
female dogs with lower urinary tract signs consistent
with a urinary tract infection. A second aim is to
evaluate recurrence rates within 4 weeks of starting anti-
microbial therapy across these different course dura-
tions. Through estimation of a duration-response curve
using fractional polynomial logistic regression, the opti-
mal treatment duration for the management of pre-
sumptive bacterial UTIs in female dogs may be
determined [34–36]. The optimal duration is here de-
fined as the shortest duration non-inferior to the control
(maximum) duration within a risk difference margin of
10 % [36] Bootstrapping can be used to estimate the
confidence intervals around the optimal duration at the
pre-specified non-inferiority margin (10 %). This analysis
approach has been shown to have good operating char-
acteristics (type-1 and type-2 errors) under a wide range
of true duration-response curves [36]. The main advan-
tage of assigning female dogs with lower urinary tract
signs consistent with sporadic cystitis to a number of
duration arms and modelling the duration-response
curve is that one does not have to select one arbitrary
shorter duration to test against the standard duration
[34–36]. This information can support future antimicro-
bial stewardship recommendations and help avoid un-
necessary antimicrobial use.
Methods and study design
Recruitment
Veterinarians working in clinical practice in the United
Kingdom have been informed about this trial through
different media including a call for involvement in the
study in a veterinary journal [37], presentation of the
protocol at the Small Animal Society’s autumn meeting
and promotion on the society website. Each participating
veterinarian has been provided with a unique login to
the electronic data capture system (see details below)
and a package of documents relating to the study (in-
cluding client consent forms, a user guide covering data
entry, a summary of all the phases of the study and cop-
ies of the inclusion and exclusion criteria). Participating
veterinarians are responsible for patient recruitment
based on pre-defined eligibility criteria.
Investigational animals
Informed consent
Only dogs that satisfy all of the inclusion criteria and to
whom none of the exclusion criteria apply will be en-
rolled. Enrollment to the study will only be possible for
dogs presenting to the participating veterinarian between
Monday and Friday inclusive. All owners must provide
written informed consent to participate in the study and
also agree to fulfil all requirements of the study. A writ-
ten version of the owner consent form and an informa-
tion sheet for owners will be presented to the owner at
initial consultation and will be verbally described by the
veterinarian. The owner consent form and information
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sheet detail the nature of the study, what it will involve
for the participant, the known side effects and any risks
involved in taking part. It is clearly stated that owners
are able to withdraw their dog from the study at any
time and that withdrawal will not affect the care of their
pet. The owner will be allowed time to consider the in-
formation and will be given the opportunity to question
the participating veterinarian prior to enrolment. A copy
of the signed owner consent form will be retained by the
owner and the original retained at the practice of the
participating veterinarian.
Inclusion and exclusion criteria
All dogs participating in this study are pets or working
dogs. All dogs must be female, at least 6 months of age
and less than 10 years of age on the day of enrollment.
Dogs presented with acute onset of one or more of the
following lower urinary tract clinical signs (pollakiuria,
dysuria/stranguria or haematuria) are eligible for inclu-
sion in the study as long as the case veterinarian intends
to prescribe antimicrobials.
The dog may not be included in the study if a non-
bacterial cause of the clinical signs is identified (e.g. uro-
lithiasis or neoplasia of the urogenital tract), if there is
suspicion of upper urinary tract involvement (presence
of abdominal/lumbar pain, pyrexia (rectal temperature >
39.5 °C)), if the dog has a history of recurrent UTIs (pre-
vious lower urinary tract signs reported in the past 28
days, three or more episodes of clinical bacterial cystitis
in the preceding 12 months or two or more episodes in
the preceding 6 months), if the dog is being currently
treated with corticosteroid therapy, insulin, trilostane or
thyroxine supplementation, if the dog has received anti-
microbials for any reason in the past 14 days, if there is
known intolerance to amoxicillin/clavulanate or if the
owners are unable to administer medications twice daily
throughout treatment period.
Study design
This trial is a prospective, quasi-randomised controlled
trial to test the efficacy of shorter durations (3,4,5 and 6
days) compared to a longer standard duration of 7 days
of antimicrobial treatment for female dogs with pre-
sumed UTI. Similar to the recently proposed DUR-
ATION design, the trial will include multiple duration
arms which will be used to estimate a duration-response
curve through fractional polynomial logistic regression.
The duration-response-curve can subsequently be used
to identify the optimal duration as proposed in Quar-
tagno et al. [36] and described in the ‘data analysis’ sec-
tion. A non-treatment control group is not included as it
would not be ethical to deprive patients of antimicrobial
treatment. Both the patient enrolment and follow-up ap-
pointments for individual cases will be held in the same
clinic. Data analysis will be performed by study investi-
gators in their respective institutions. Throughout the
trial, participants will be kept in their home environment
where reporting of clinical signs will occur.
The monitoring site for this trial is Willows Veterinary
Centre and Referral Service, which will oversee the logis-
tical progression of the study under the supervision of
the Chief Investigator. This study is conducted in ac-
cordance with veterinary Good Clinical Practice (GCP)
guidelines ((i) International Cooperation on Harmonisa-
tion of Technical Requirements for Registration of Vet-
erinary Products (VICH) GL9 Good Clinical Practices
(July, 2001), (ii) The European Agency for the Evaluation
of Medicinal Products (EMEA) Guideline on statistical
principles for veterinary clinical trials, EMEA/CVMP/
816/00-FINAL (June 5, 2002)). The study is approved by
the Ethical Review Board of the University of Notting-
ham (REF 3007 191,023).
Electronic data collection platform
Data will be submitted through an Electronic Data Cap-
ture platform (CASTOR™) [38]. This platform can be
used by multiple clinics at the same time and is updated
live. The use of this platform facilitates compliance with
medical data privacy, security, and GCP regulations. Par-
ticipating veterinarians will complete study forms to rec-
ord information about the dog on the day of enrolment,
the Monday after completion of the antimicrobial course
and 3 weeks later. Dogs will be automatically assigned a
unique study number for identification purposes ensur-
ing that all follow-up information from the participating
veterinarian or from the owner is added to the specific
clinical record. Web links to questionnaires will be auto-
matically distributed to the owners via email 7 days after
completion of the antimicrobial course and 28 days after
initial presentation. Owners without access to the inter-
net will be given a paper version of the same question-
naire or it may be completed on their behalf by the
participating veterinarian using information provided by
the owner.
Initial presentation
Any eligible dog presenting to participating veterinarians
with compatible lower urinary tract signs will be consid-
ered for enrolment in the trial. Support material, includ-
ing details of the inclusion and exclusion criteria, has
been prepared for participating veterinarians (see supple-
mentary information). A complete clinical history will be
taken and physical examination performed by the par-
ticipating veterinarian. Demographic data including neu-
ter status, bodyweight, body condition score, age and
breed will be entered into a study form on the electronic
data capture platform. The presence (and duration) of
macroscopic haematuria (presence of red blood cells in
Allerton et al. BMC Veterinary Research          (2021) 17:299 Page 4 of 12
the urine), pollakiuria (increased frequency of urination)
and dysuria/stranguria (straining and difficulty to pass
urine) will also be recorded.
Any additional tests or investigations (e.g. urinalysis
or abdominal imaging) will be offered and completed
at the participating veterinarian’s discretion before
treatment commences. For inclusion in the study,
cytological evidence supporting bacterial cystitis (e.g.
pyuria, bacteriuria) or positive bacterial culture results
are not required as these tests are not deemed
mandatory examinations in standard clinical practice
at first presentation. However, should these investiga-
tions be performed, the information will be entered
into the dog’s electronic record. Dogs with evidence
of a non-bacterial cause for the clinical signs will be
excluded from the study.
At this consultation informed consent will be obtained
from the owner after the initial eligibility check is com-
pleted. Dogs enrolled in the study will be prescribed the
appropriate duration of antimicrobial treatment (number
of doses) determined by the day of presentation to the
clinic (Table 1). For the purposes of this study, only
authorised preparations of amoxicillin-clavulanate will
be prescribed as antimicrobial therapy. An Animal Test
Certificate (ATC-S-130) has been obtained from the
Veterinary Medicines Directorate covering the use of
formulations of amoxicillin-clavulanate with a marketing
authorisation in the United Kingdom for a variable treat-
ment duration. In accordance with the marketing
authorisations, a set dose of 12.5 mg/kg PO q12h should
be rounded up to the nearest possible tablet size or frac-
tion that can be administered. Tablets may be divided by
the owner, if appropriate for the particular product dis-
pensed according to instructions in the marketing au-
thorisation. Tablets may be crushed for administration if
necessary to ensure compliance.
Each dog will start antimicrobial treatment immedi-
ately and the treatment will be continued twice daily
until the next Sunday evening (two treatments to be
administered on the Sunday). Antimicrobial treatment
will be stopped on Sunday evening (Table 2 and Fig. 1).
Monday after presentation
All owners should update the case clinician (or a col-
league) on the Monday (Day 1) having completed the
variable duration antimicrobial treatment course the day
before. Follow-up communication should be completed
on the specified day and repeat efforts should be made
on the Tuesday to contact any owners that have not pro-
vided an update. The participating veterinarian should
complete the relevant study form on the electronic data
capture platform detailing the adherence to the treat-
ment course (number of doses misses), resolution or
persistence of clinical signs and any further treatment
administered or investigations performed. Clinical reso-
lution will be based on the absence of lower urinary tract
signs (haematuria, pollakiuria or dysuria/stranguria).
Any dogs with persistence of any of the lower urinary
tract signs will be managed at the discretion of the par-
ticipating veterinarian. In these cases the decision for
further management will be classified as either extension
of amoxicillin-clavulanate, prescription of a different
antimicrobial or discontinuation of antimicrobial ther-
apy. Further diagnostic investigations performed at this
stage will also be recorded; dogs that subsequently have
a non-bacterial cause for the clinical signs identified will
be censored from certain data analyses. Any additional
treatment will be provided until the clinical signs are
controlled, or additional investigations undertaken, as
appropriate for the individual case and under the super-
vision of the case clinician.
Additional follow-up
Online surveys will be automatically sent to owners 7
days after completion of the antimicrobial course (short-
term follow up) and 28 days after initial presentation (to
measure recurrence). These short surveys will confirm
timing of resolution of clinical signs and whether the
Table 1 Schedule of antimicrobial treatment
Day/time of presentation Monday Tuesday Wednesday Thursday Friday Saturday Sunday Total doses
Mon. AM * * * * * * * 14
Mon. PM * * * * * * * 13
Tues. AM * * * * * * 12
Tues. PM * * * * * * 11
Wed. AM * * * * * 10
Wed. PM * * * * * 9
Thur. AM * * * * 8
Thur. PM * * * * 7
Fri. AM * * * 6
Fri. PM * * * 5
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owner has observed any recurrence of lower urinary
tract signs since completion of antimicrobial treatment.
The data may also be inputted by the case clinician after
speaking to the owner by telephone or consulting with
them in person if the owner is unable to complete the
survey themselves.
A study form will also be completed by the case veter-
inarian 28 days after initial presentation. This will record
any re-presentation of the dog to the practice and detail
any additional investigations that have been performed
or treatments prescribed.
Unexpected events
In the event of unexpected complications, owners will
be able to contact their veterinary practice directly at
any time and make use of their normal 24 h emergency
care provision. The electronic data capture platform in-
cludes the facility to input details of unscheduled events
including presentation for clinical deterioration, poten-
tial adverse reactions associated with the antimicrobial
treatment, euthanasia, death or consultation for another
unrelated condition.
Primary and secondary objectives (Table 3)
The primary, secondary and exploratory objectives will
be followed to compare the efficacy of shorter durations
(3,4,5,6) with the standard duration of 7 days of anti-
microbial treatment for the management of presumed
UTI.
Neither owners nor participating veterinarians will be
blinded to the duration of antimicrobial treatment for
that patient. The veterinarian prescribing the







7 days after completion
antimicrobials















Fig. 1 Infographic provided to participating veterinarians outlining key time points in the study
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antimicrobial (or a colleague at the same practice) will
also be responsible for follow-up appointments and
assessing clinical signs to determine response to treat-
ment. Blinding of technical analysis personnel to treat-
ment groups will be conducted through the electronic
data capture platform as necessary. Un-blinding of the
co-investigators will occur following completion of the
primary statistical analysis.
Data analysis
After study completion, the data will be collated, and
statistical analysis will be performed using R (Vienna,
Austria [gamlss package]) and Prism® (GraphPad Soft-
ware, San Diego, USA).
Dogs will be grouped according to the number of days
of treatment prescribed (3, 4, 5, 6 or 7 days). Compari-
son of these groups at baseline will be performed to look
for any potential confounding factors that could bias the
results (e.g. different durations of clinical signs prior
consultation). Differences in group composition will also
be verified for age, neuter status, previous history of
UTIs and presence of chronic kidney disease. For con-
tinuous parameters, descriptive statistics will be calcu-
lated and tabulated for each group. If data are normally
distributed, the mean and standard deviation will be cal-
culated, while median and interquartile range will be
cited for skewed data. Comparisons between the groups
will be made using match-paired Student’s t-tests for
parametric data and Wilcoxon matched-pairs signed
rank test for non-parametric data.
The primary and secondary analyses will be analysed
by estimating duration-response curves using a frac-
tional polynomial logistic model with duration as the
only covariate and two polynomial terms [35, 36]. Subse-
quently, the optimal duration is estimated from this
curve by finding the minimum duration D* correspond-
ing to a cure rate that is still within the pre-specified
margin of 10 % of the efficacy of the longest duration of
7 days. The optimal duration will be estimated from the
duration-response curves by bootstrapping – resample
1000 times the observed dataset with replacement – to
directly estimate the optimal duration in each bootstrap,
where the optimal duration is defined as the shortest
duration that falls within the non-inferiority margin of
10 % (risk difference) of the efficacy of the maximum
duration of 7 days. A bootstrap 95 % confidence interval
will be constructed from the bootstrap mean estimate
and its standard error. The recommended duration
would be the shortest duration that is larger than the es-
timated upper limit of the 95 % confidence interval [36].
This methodology of using the duration-response curves
has been shown to have good inferential properties (type
I and II error) in extensive simulations [36].
Sensitivity analyses
Because there is a perfect correlation between day of
presentation and assigned duration, results may be con-
founded by systematic differences in severity of illness
when presenting just before or after the weekend com-
pared to the rest of the week. If severity of illness would
be worse on Monday because owners wait until the
weekend has passed, one could erroneously chose a dur-
ation that is too short as optimal. We will explore the
sensitivity of our results to such a weekend effect by ex-
ploring how strong and common such an unmeasured
severity-of-illness confounder would have to be to draw
the wrong conclusion about the optimal duration. Add-
itional covariates besides the time since onset of first
sign(s) will be considered for inclusion in the model in
sensitivity analysis, including concurrent clinical signs
(haematuria, pollakiuria and dysuria/stranguria).
Acknowledging that not all veterinarians would agree
on what the minimum treatment efficacy they would
find acceptable for shorter than the maximum duration
Table 3 Objectives and Outcome Measures





To compare disease-related outcome measures in dogs
with presumed urinary tract infection treated with different
duration (3, 4, 5, 6 or 7 day) regimens of amoxicillin/clavu-
lanate. Find the shortest duration that is non-inferior to a
duration of 7 days:
Optimal treatment duration in terms of proportion of
dogs with resolution of lower urinary tract clinical signs as
reported by the owner. Optimal is here defined as the
shortest duration that is non-inferior to a duration of 7
days. The non-inferiority margin is set at 10 % [36].
1 day post treatment
completion
Secondary Objectives
To compare recurrence rates within the 4 weeks of initial
presentation after completion of different duration (3, 4, 5,
6 or 7 day) regimens of amoxicillin/clavulanate
Proportion of dogs developing recurrence of lower
urinary tract signs within 4 weeks of initial presentation
28 days after initial
presentation
Exploratory Objectives
In cases where urine culture is performed (not
compulsory), to compare among groups:
Percentage of culture positive pre-treatment samples
Percentage where bacteriological cure achieved
All
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of 7 days – a pre-specified margin of 10 % in our main
analysis – we will explore for a range of margins that
could be deemed acceptable (range 0–20 %) to deter-
mine what the optimal duration would be. We will esti-
mate 95 % confidence intervals around the difference in
the response between each duration (3, 4, 5, and 6 days)
and the longest duration (7 days) using bootstrapping.
This will subsequently be visualized by plotting the dur-
ation on the x-axis and the estimated difference and cor-
responding confidence intervals in response on the y-
axis as done in Figure 4 in Quartagno et al. This allows
a comparison with any (duration-specific) non-
inferiority margin.
Sample size calculation
Sample size calculations were performed using simula-
tions by modifying code that was developed and shared
by Quartagno et al. [35] Several hypothetical duration-
response curves (Fig. 2) were considered to guide the
sample size calculations. To achieve 95 % of simulated
trials leading to a duration-response curve whose error
in the estimation of the probability of clinical cure was
under 5 % for most hypothetical curves (95th percentile
scaled area between curves (sABC) < 0.05) an effective
sample size of 700 would be required (this figure would
also be sufficient for comparison of recurrence data).
However, it must be remembered that not all dogs en-
rolled within this study will have a UTI. Given the strin-
gent inclusion criteria it is estimated that the percentage
of dogs with a genuine UTI in this study will be 75 %.
Therefore, without any dropouts the required sample
size would be 700 / 0.75 = 934 dogs. With a non-
inferiority margin of 10 % and an effective sample size of
700 participants a fixed-2 fractional polynomial model
demonstrated robustness against a range of duration-
response curves in simulations in terms of absolute error
(< 5 % across most scenarios), acceptable power (> 90 %
across most scenarios) and Type-I error (< 0.025 across
most scenarios) [35, 36].
An effective sample size of 650 dogs still achieves a
sABC < 0.05 for the Gompertz model C requiring re-
cruitment of 650 / 0.75 = 867 dogs. Assuming that the
majority of UTI cases that respond to antimicrobial ther-
apy should do so within 48 h, the Gompertz model C
would seem a priori the most likely true duration-
response curve. Nevertheless, the use of a flexible frac-
tional polynomial will ensure that other underlying
shapes of the duration-response curve can be adequately
estimated. In either case a projected sample size of
nearly 900 dogs is ambitious. Interim analysis is pro-
posed upon enrollment of 33 % cases (300 cases), or
after 2 years of recruitment, whichever event comes
sooner.
Discussion
While several previous studies have compared defined
treatment durations of different antimicrobial treat-
ments, the approach outlined here is novel in (veterin-
ary) medicine. By assigning patients to a number of
duration arms and estimating a duration-response curve,
the optimal antibiotic treatment duration can be esti-
mated. This has several advantages compared to more
traditional comparisons of a control duration and an
often arbitrarily chosen shorter duration, which may well
be not the optimal duration. For example, if 3 days is
not non-inferior to 7 days, but 4 days is non-inferior to
7 days, the optimal duration identified by a standard 3
vs. 7 days non-inferiority trial would be 7 days, while a
multi-arm DURATION design would identify 4 days as
the optimal duration. By evaluating multiple durations
in one trial one avoids erosion of efficacy from testing
for non-inferiority for increasingly shorter durations in
sequential trials with updated control durations, thereby
avoiding the so-called ‘bio-creep’ [36, 39]. Furthermore,
the design maintains good properties against a wide
range of duration-response curves, while standard non-
inferiority trials are vulnerable to losing power or inter-
pretability if a single design parameter has been misspe-
cified [36].
By estimating the optimal treatment duration for pre-
sumptive UTI, this study should support veterinarians to
determine course lengths for similar presentations and
ensure optimal antimicrobial use for a common canine
affliction. The abbreviated name for this study – stop on
Sunday (SOS), highlights the method of assignment of
different treatment durations. All initial antimicrobial
courses will be prescribed to complete on the Sunday
evening after presentation. Therefore, dogs presenting
on Monday will receive a 7-day antimicrobial course,
those on Tuesday will receive 6 days’ worth of treatment
and so forth. This per diem method of randomization
was selected to facilitate effective safety-netting for the
patient. By synchronizing case follow-up to a Monday,
within 24 h of completion of the initial antimicrobial
course, the participating veterinarian will have the op-
portunity to re-assess the case and enact appropriate
diagnostic or therapeutic steps appropriate to the re-
ported clinical response.
It may be argued that the day of presentation is not a
genuine random variable; confounding factors could
contribute to an uneven distribution of case presenta-
tions across the working week both in terms of the num-
ber of cases and case-severity. For example, owners may
delay presentation over a weekend (reduced appoint-
ment availability) or conversely, present sooner, in an-
ticipation of the weekend (same reasoning).
Quantification of such factors is difficult and this meth-
odology represents a limitation to the study, although
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Fig. 2 Hypothetical duration response curves to guide sample size calculations.
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measures of disease severity including separately the
duration of pollakiuria, haematuria and dysuria/stran-
guria and the presence/absence of additional systemic
clinical signs will be recorded and compared. Sensitivity
analysis will be presented that will explore how large
such effects should be to prompt the wrong inference
about optimal treatment duration. However, this ap-
proach to randomisation does confer 2 notable advan-
tages. Firstly, early outcome reporting on a Monday
optimises the opportunity to adjust patient management
protecting patient safety. Secondly, the process of group
allocation is rapid and straightforward avoiding unneces-
sary delays during the consultation.
Consistent with National and International guideline
documents, submission of urine culture is recommended
as part of this study protocol. However, it has not been
made a mandatory inclusion criterion. Empiric therapy
without confirmation of diagnosis risks aggravating anti-
microbial resistance [40]; any decision to treat must be
based on a strong index of clinical suspicion. How
confident one needs to be to justify empiric antimicro-
bial use remains a controversial topic. A threshold of
70 % probability of infection may be regarded as suffi-
cient based on recommendations for management of un-
complicated cystitis in women [41, 42]. Accurate patient
selection in this context is therefore crucial to minimise
inappropriate treatment. The pre-test probability of UTI
has been previously investigated in dogs [15] and people
[43, 44]. Although confirmed bacterial infection was only
found in 46 to 65 % of dogs presenting with one or more
lower urinary tract signs [13–15, 45], by focusing on a
narrow, increased-risk population (exclusively female
dogs), the positive predictive value of each lower urinary
tract sign should be greater than the values described for
all dogs. The ultimate decision to enrol any dog requires
an intention of the participating veterinarian to prescribe
antimicrobial therapy. We estimate that 75 % of dogs
treated on this basis will have a bacterial UTI.
The primary outcome of this study (clinical cure by
the end of the treatment course) is dependent on the
short term clinical cure rates for female dogs with
sporadic cystitis treated with amoxicillin-clavulanate,
previously found to be between 70 and 88 % [26,
27]. A clinical cure rate of 75 % for this study popula-
tion has been assumed. For the secondary outcome,
(recurrence rates within 3 weeks of completion of
treatment), a recurrence rate of 10 % has been extrap-
olated [27]. Limited data is available to support this
assumption.
In-vitro susceptibility to amoxicillin-clavulanate was
found in 83 % of isolates from uncomplicated canine
UTIs [24]. Even greater in-vivo efficacy may be antici-
pated as amoxicillin is concentrated in urine. Al-
though greater in-vitro susceptibility to trimethoprim-
sulphamethoxazole was found (90.3 %) [24];
authorised preparations of this antimicrobial are not
currently commercially available in the UK. Culture
and susceptibility testing is particularly important
when antimicrobial therapy has previously been ad-
ministered; in vitro resistance was higher in dogs
treated in the last 30 days with antimicrobials [24].
This finding underlies the exclusion criteria relating
to recent antimicrobial use in this study.
Recent guidance from the European Medicines Agency
(EMA), prepared by the Antimicrobial Advice Ad Hoc
Expert Group (AMEG), takes account of the need to use
antimicrobials in animals versus the risk of antimicrobial
resistance to public health [46]. Importantly,
amoxicillin-clavulanate has been placed in Category C
(Caution) while the aminopenicillins (e.g. amoxicillin)
are Category D (Prudence). This reflects concerns that
the overuse of beta-lactamase inhibitors will drive selec-
tion for resistance towards penicillins and cephalospo-
rins, including the higher generation cephalosporins, in
both Gram-negative bacteria (e.g. ESBL) and in staphylo-
cocci (e.g. MRSA). Further the ISCAID guidelines state
that evidence supporting a need for clavulanic acid in
the treatment of sporadic cystitis is not established[5].
Selection of a narrower spectrum antimicrobial (amoxi-
cillin) would adhere more closely to key antimicrobial
principles. However, where amoxicillin is not widely
available or used (as the latest Veterinary Antimicrobial
Resistance and Sales Surveillance (VARSS) data for anti-
microbial use in the UK indicates [47]), the use of
amoxicillin-clavulanate is reasonable [5]. Given the large
sample size required in this study, amoxicillin-
clavulanate was selected to facilitate maximal practice
recruitment.
This study has been purposefully designed to mirror
current standard clinical practice; findings should, there-
fore, be applicable to a commonly-encountered situation
supporting veterinarians in their decision making
process. This study is the first in veterinary medicine to
try to establish an optimal treatment duration for any in-
fectious disorder and, if successful, will represent the lar-
gest participation trial undertaken to date. It is hoped
that the results of this process will provide valuable in-
formation to guide antimicrobial therapy in the future
and further antimicrobial stewardship as part of a wider
one-health perspective.
Abbreviations
AMR: Antimicrobial resistance; BSAVA: British Small Animal Veterinary
Association; DALY: Disability-adjusted life-year; EMEA: European Agency for
the Evaluation of Medicinal Products; FECAVA: Federation of European
Companion Animal Veterinary Associations; GCP: Good Clinical Practice;
HIV: Human immunodeficiency virus; MIC: Minimum inhibitory concentration;
ISCAID: International Society for Companion Animal Infectious Diseases;
Allerton et al. BMC Veterinary Research          (2021) 17:299 Page 10 of 12
SAMSoc: Small Animal Medicine Society; sABC: Scaled area between curves;
SOS: Stop on Sunday; UTI: Urinary tract infection
Supplementary Information






The study protocol was conceived and designed by FA and AK and
amended following review by KBP, JB, AC, SC, LDR, JS and JW. KBP
performed sample size calculations and has prepared the sections on
statistical analysis. All authors read and approved the final manuscript.
Funding
The Small Animal Medicine Society (SAMSoc) paid the subscription costs for
the electronic data capture system. KBP is supported by the National
Institute for Health Research (NIHR) Health Protection Research Unit (HPRU)
in Healthcare Associated Infections and Antimicrobial Resistance at the
University of Oxford in partnership with Public Health England (PHE;
NIHR200915). JW is a Wellcome Trust Clinical PhD Fellow; his PhD is funded
by Wellcome Trust. The views expressed are those of the authors and not
necessarily those of the National Health Service, NIHR, Department of Health,
or PHE.
Availability of data and materials
The datasets used and/or analysed during the current study will be made
available from the corresponding author on reasonable request. Datasets will
be presented within a final manuscript and/or included as additional
supporting files as appropriate. No identifying/confidential patient data will
be shared.
Declarations
Ethics approval and consent to participate
The study is approved by the Ethical Review Board of the University of
Nottingham (REF 3007 191023). An Animal Test Certificate (ATC-S-130) has
been obtained from the Veterinary Medicines Directorate covering the use
of formulations of amoxicillin-clavulanate with a marketing authorisation in
the United Kingdom for a variable treatment duration. Informed consent will




The authors declare that they have no competing interests.
Author details
1Willows Veterinary Centre and Referral Service; part of Linnaeus Veterinary
Limited, Highlands Road, Shirley, Solihull, UK. 2Health Economics Research
Centre, Nuffield Department of Population Health, University of Oxford,
Oxford, UK. 3NIHR Health Protection Research Unit in Healthcare Associated
Infections and Antimicrobial, Oxford, UK. 4Resistance at University of Oxford
in partnership with Public Health England, Oxford, UK. 5Davies Veterinary
Specialists; part of Linnaeus Veterinary Limited, Manor Farm Business Park,
Higham Gobion, Hitchin, UK. 6Cambridge Institute for Therapeutic
Immunology and Infectious Disease, Jeffery Cheah Biomedical Centre,
Puddicomb Way, Cambridge Biomedical Campus, Cambridge, UK. 7Beechley
Farm, Park Hall Road, Gosfield, Essex, UK. 8Linnaeus Veterinary Limited, Friars
gate, Shirley, Solihull, UK. 9Columbia Stem Cell Initiative, Columbia University,
650 West 168th Street, NY 10032 New York, USA. 10Wellcome-MRC
Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of
Cambridge, Puddicombe Way, Cambridge, UK. 11Willows Veterinary Centre
and Referral Service; part of Linnaeus Veterinary Limited, Highlands Road,
Shirley, Solihull, UK.
Received: 2 February 2021 Accepted: 20 July 2021
References
1. Cassini A, Diaz Högberg L, Plachouras D, et al. Attributable deaths and
disability-adjusted life-years caused by infections with antibiotic-resistant
bacteria in the EU and the European Economic Area in 2015: a population-
level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66.
2. Jessen LR, Damborg P, Spohr A, et al. Antimicrobial Use Guidelines for
Companion Animal Practice [Antibiotikavejledning til familiedyr]. 2nd ed.
Copenhagen: Den Danske Dyrlægeforenings Sektion for Hund; 2018.
3. Hillier A, Lloyd DH, Weese JS, et al. Guidelines for the diagnosis and
antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial
Guidelines Working Group of the International Society for Companion
Animal Infectious Diseases). Vet Dermatol. 2014;25:163-e43.
4. Lappin MR, Blondeau J, Boothe D, et al. Antimicrobial use guidelines for
treatment of respiratory tract disease in dogs and cats: Antimicrobial
Guidelines Working Group of the International Society for Companion
Animal Infectious Diseases. J Vet Intern Med. 2017;31(2):279–94.
5. Weese JS, Blondeau J, Boothe D, et al. International Society for companion
animal infectious diseases (ISCAID) guidelines for the diagnosis and
management of bacterial urinary tract infections in dogs and cats. Vet J.
2019;247:8–25.
6. Lutz B, Lehner C, Schmitt K, et al. Antimicrobial prescriptions and adherence
to prudent use guidelines for selected canine diseases in Switzerland in
2016. Vet Rec Open. 2020;7:e000370.
7. Rantala M, Huovinen P, Holso K, Lilas A, Kaartinen L. Survey of condition-
based prescribing of antimicrobial drugs for dogs at a veterinary teaching
hospital. Vet Rec. 2004;155(9):259–62.
8. Gómez-Poveda B, Moreno MA. Antimicrobial Prescriptions for Dogs in the
Capital of Spain. Front Vet Sci. 2018;5:309.
9. De Briyne N, Atkinson J, Pokludová L, Borriello SP. Antimicrobials used most
commonly to treat animals in Europe. Vet Rec. 2014;175(13):325.
10. Ling GV. Therapeutic strategies involving antimicrobial treatment of the
canine urinary tract. J Am Vet Med Assoc. 1984;10:1162–4.
11. Adamama-Moraitou KK, Pardali D, Prassinos NN, et al. Evaluation of dogs
with macroscopic haematuria: a retrospective study of 162 cases (2003–
2010). N Z Vet J. 2017;65:204–8.
12. KivistÖ A-K, Vasenius H, Sandholm M. Canine bacteruria. J Small Anim Pract.
1977;18(11):707–12.
13. Sørensen TM, Bjørnvad CR, Cordoba G, et al. Effects of diagnostic work-up
on medical decision-making for canine urinary tract infection: an
observational study in Danish small animal practices. J Vet Intern Med. 2018;
32:743–51.
14. Windahl U, Holst BS, Nyman A, et al. Characterisation of bacterial growth
and antimicrobial susceptibility patterns in canine urinary tract infections.
BMC Vet Res. 2014;10:217.
15. Sørensen TM, Holmslykke M, Nordlund M, Siersma V, Jessen LR. Pre-test
probability of urinary tract infection in dogs with clinical signs of lower
urinary tract disease. Vet J. 2019;247:65–70.
16. Weese JS, Blondeau JM, Boothe D, et al. Antimicrobial use guidelines for
treatment of urinary tract disease in dogs and cats: Antimicrobial guidelines
working group of the international society for companion animal infectious
diseases. Vet Med Int. 2011;2011(4):1–9.
17. Ironmonger D, Edeghere O, Gossain S, Hawkey. PM Use of antimicrobial
resistance information and prescribing guidance for management of urinary
tract infections: survey of general practitioners in the West Midlands. BMC
Infect Dis. 2016;16:1–6.
18. Ganzeboom KMJ, Uijen AA, Teunissen DTAM, Assendelft WJJ, Peters HJG,
Hautvast JLA, Van Jaarsveld CHM. Urine cultures and antimicrobials for
urinary tract infections in Dutch general practice. Prim Health Care Res Dev.
2019;20(e41):1–8.
19. Spek M, Cals JWL, Oudhuis GJ, et al. Workload, diagnostic work-up and
treatment of urinary tract infections in adults during out-of-hours primary
care: a retrospective cohort study. BMC Fam Pract. 2020;21:231.
20. Burke S, Black V, Sánchez-Vizcaíno F, Radford A, Hibbert A, Tasker S. Use of
cefovecin in a UK population of cats attending first-opinion practices as
recorded in electronic health records. J Feline Med Surg. 2016;19(6):687–92.
Allerton et al. BMC Veterinary Research          (2021) 17:299 Page 11 of 12
21. European Surveillance of Veterinary Antimicrobial Consumption (ESVAC)




22. Mateus A, Brodbelt DC, Barber N, Stärk. KDC Antimicrobial usage in dogs
and cats in first opinion veterinary practices in the UK. J Small Anim Pract.
2011;52:515–21.
23. Hall JL, Holmes MA, Baines SJ. Prevalence and antimicrobial resistance of
canine urinary tract pathogens. Vet Rec. 2013;173:549.
24. Wong C, Epstein SE, Westropp JL. Antimicrobial susceptibility patterns in
urinary tract infections in dogs (2010–2013). J Vet Intern Med. 2015;29(4):
1045–105.
25. Smee N, Lloyd K, Grauer GF. UTIs in Small Animal Patients: Part 2: Diagnosis,
Treatment, and Complications. J Am Anim Hosp Assoc. 2013;49(2):83–94.
26. Cotard JP, Gruet P, Pechereau D, Moreau P, et al. Comparative study of
marbofloxacin and amoxicillin clavulanic acid in the treatment of urinary
tract infections in dogs. J Small Anim Pract. 1995;36:349–53.
27. Westropp JL, Sykes JE, Irom S, et al. Evaluation of the efficacy and safety of
high dose short duration enrofloxacin treatment regimen for
uncomplicated urinary tract infections in dogs. J Vet Intern Med. 2012;26(3):
506–12.
28. Clare S, Hartmann FA, Jooss M, et al. Short- and long-term cure rates of
short-duration trimethoprim-sulfamethoxazole treatment in female dogs
with uncomplicated bacterial cystitis. J Vet Intern Med. 2014;28(3):818–26.
29. Jessen LR, Sørensen TM, Bjornvad CR, Nielsen SS, Guardabassi. L Effect of
antimicrobial treatment in canine and feline urinary tract infections: a
systematic review. Vet J. 2015;203(3):270–7.
30. Spellberg B. The New Antibiotic Mantra-"Shorter Is Better". JAMA Intern
Med. 2016;176(9):1254-5.
31. Spellberg B, Rice LB. Duration of antimicrobial therapy: shorter is better. Ann
Intern Med. 2019;171(3):210–1.
32. Pouwels KB, Hopkins S, Llewelyn MJ, Walker AS, et al. Duration of antibiotic
treatment for common infections in English primary care: cross sectional
analysis and comparison with guidelines. BMJ. 2019;364:l440.
33. Vaughn VM, Flanders SA, Snyder A, et al. Excess antimicrobial treatment
duration and adverse events in patients hospitalized with pneumonia. A
multihospital cohort study. Ann Intern Med. 2019;171:153–63.
34. Pouwels KB, Yin M, Butler CC, et al. Optimising trial designs to identify
appropriate antibiotic treatment durations. BMC Med. 2019;17:115.
35. Quartagno M, Walker AS, Carpenter JR, Phillips PP, Parmar MK. Rethinking
non-inferiority: a practical trial design for optimising treatment duration.
Clin Trails. 2018;15(5):477–88.
36. Quartagno M, Carpenter JR, Walker AS, Clements M, Parmar MK. The
DURATIONS randomised trial design: Estimation targets, analysis methods
and operating characteristics. Clin Trails. 2020;17(6):644–53.
37. Allerton F, Kent A. How to approach urinary tract infections. Companion
2020.
38. Electronic Data Capture (EDC). eCRF, ePRO, eCOA for clinical research |
Castor. In: Castor EDC. https://www.castoredc.com/. Accessed 10 Dec 2020.
39. MacFadden DR, Hanage WP. Potential for Erosion of Efficacy in
Noninferiority Trials of Decreasing Duration of Antibiotic Therapy. Clin Infect
Dis. 2019;69(7):1262.
40. Butler CC, Dunstan F, Heginbothom M, Mason B, Roberts Z, Hillier S, Howe R,
Palmer S, Howard A. Containing antibiotic resistance: decreased antibiotic-
resistant coliform urinary tract infections with reduction in antibiotic
prescribing by general practices. Br J Gen Pract. 2007;57(543):785–92.
41. McIsaac WJ, Moineddin R, Ross S. Validation of a decision aid to assist
physicians in reducing unnecessary antibiotic drug use for acute cystitis.
Arch Intern Med. 2007;167(20):2201–6.
42. McIsaac WJ, Moineddin R, Gagyor I, Mazzulli T. External validation study of a
clinical decision aid to reduce unnecessary antibiotic prescriptions in
women with acute cystitis. BMC Fam Pract. 2017;18:89.
43. Bent S, Nallamothu BK, Simel DL, et al. Does this woman have an acute
uncomplicated urinary tract infection? JAMA. 2002;287(20):2701–10.
44. Giesen LG, Cousins G, Dimitrov BD, et al. Predicting acute uncomplicated
urinary tract infection in women: a systematic review of the diagnostic
accuracy of symptoms and signs. BMC Fam Pract. 2010;11:78.
45. Brloznik M, Sterk K, Zdovc I. Prevalence and resistance patterns of canine
uropathogens in regard to concurrent diseases. Berl Munch Tierarztl
Wochenschr. 2016;129:340–50.









Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Allerton et al. BMC Veterinary Research          (2021) 17:299 Page 12 of 12
